Capitalizator.

Capitalize Yourself: Right Data. Real Growth.

Company Analysis

NTRA Insider Trading

Natera, Inc. | Services-Medical Laboratories

Comprehensive Trading Performance Summary

The investment history of corporate insiders at Natera, Inc. provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Services-Medical Laboratories sector.

Transactions on Chart

Open Full Chart
Filing Date Trade Date Reporting Person Relationship Type Price Qty Total, $ Owned After Change, %
2024-08-15 04:05 2024-08-13 Fesko John Officer - PRESIDENT, CHIEF BUS. OFFICER SELL $116.67 3,956 $461,547 114,606 -3.3%
2024-08-01 04:05 2024-07-29 RABINOWITZ DANIEL Officer - SEC. AND CHIEF LEGAL OFFICER SELL $102.77 1,057 $108,623 206,400 -0.5%
2024-08-01 04:05 2024-07-29 Moshkevich Solomon Officer - PRESIDENT, CLINICALDIAGNOSTICS SELL $102.77 1,196 $122,908 112,441 -1.1%
2024-08-01 04:05 2024-07-29 Fesko John Officer - PRESIDENT, CHIEF BUS. OFFICER OPT+S $102.77 929 $95,469 108,462 0.0%
2024-08-01 04:05 2024-07-29 Chapman Steven Leonard Director, Officer - CEO AND PRESIDENT SELL $102.77 4,084 $419,695 206,293 -1.9%
2024-08-01 04:05 2024-07-29 Brophy Michael Burkes Officer - CHIEF FINANCIAL OFFICER SELL $100.89 3,104 $313,171 71,955 -4.1%
2024-07-27 04:40 2024-07-24 Brophy Michael Burkes Officer - CHIEF FINANCIAL OFFICER SELL $104.39 2,359 $246,264 75,059 -3.0%
2024-07-24 04:40 2024-07-22 Brophy Michael Burkes Officer - CHIEF FINANCIAL OFFICER OPT+S $105.88 1,558 $164,956 77,418 0.0%
2024-07-24 04:05 2024-07-22 Moshkevich Solomon Officer - PRESIDENT, CLINICALDIAGNOSTICS SELL $105.16 549 $57,733 113,637 -0.5%
2024-07-24 04:05 2024-07-22 Fesko John Officer - PRESIDENT, CHIEF BUS. OFFICER SELL $105.16 549 $57,732 109,391 -0.5%
2024-07-24 04:05 2024-07-22 Chapman Steven Leonard Director, Officer - CEO AND PRESIDENT OPT+S $105.16 2,638 $277,410 210,377 0.0%
2024-07-24 04:05 2024-07-22 RABINOWITZ DANIEL Officer - SEC. AND CHIEF LEGAL OFFICER OPT+S $105.16 815 $85,704 207,457 0.0%
2024-07-18 04:05 2024-07-15 Chapman Steven Leonard Director, Officer - CEO AND PRESIDENT SELL $111.66 5,496 $613,672 207,855 -2.6%
2024-07-03 04:05 2024-07-01 Sheena Jonathan Director, Other SELL $108.87 2,700 $293,945 301,808 -0.9%
2024-07-03 04:05 2024-07-01 RABINOWITZ DANIEL Officer - SEC. AND CHIEF LEGAL OFFICER OPT+S $108.37 2,723 $295,080 206,772 0.0%
2024-07-03 04:05 2024-07-01 Chapman Steven Leonard Director, Officer - CEO AND PRESIDENT OPT+S $108.10 37,500 $4,053,806 213,351 0.0%
2024-07-03 04:05 2024-07-01 Brophy Michael Burkes Officer - CHIEF FINANCIAL OFFICER OPT+S $108.37 4,983 $539,987 75,059 0.0%
2024-06-22 04:05 2024-06-18 Sheena Jonathan Director, Other SELL $109.66 2,700 $296,080 304,508 -0.9%
2024-06-19 04:35 2024-06-17 Chapman Steven Leonard Director, Officer - CEO AND PRESIDENT SELL $111.61 6,105 $681,372 213,351 -2.8%
2024-06-01 04:05 2024-05-30 Marcus Gail Boxer Director SELL $110.17 2,000 $220,330 18,634 -9.7%
2024-05-31 04:05 2024-05-28 Moshkevich Solomon Officer - PRESIDENT, CLINICALDIAGNOSTICS SELL $109.96 1,647 $181,103 114,186 -1.4%
2024-05-31 04:05 2024-05-28 Fesko John Officer - PRESIDENT, CHIEF BUS. OFFICER SELL $109.96 1,438 $158,122 109,940 -1.3%
2024-05-31 04:05 2024-05-28 Chapman Rowan E Director SELL $109.09 4,856 $529,728 5,005 -49.2%
2024-05-25 04:05 2024-05-23 Sheena Jonathan Director, Other SELL $108.30 1,000 $108,301 68,582 -1.4%
2024-05-18 04:35 2024-05-15 Chapman Steven Leonard Director, Officer - CEO AND PRESIDENT SELL $107.08 6,779 $725,911 219,456 -3.0%
2024-05-11 04:35 2024-05-10 RABINOWITZ DANIEL Officer - SEC. AND CHIEF LEGAL OFFICER OPT+S $104.59 30,000 $3,137,568 204,495 0.0%
2024-05-11 04:35 2024-05-10 Sheena Jonathan Director, Other SELL $105.11 2,700 $283,794 319,061 -0.8%
2024-05-04 04:35 2024-05-01 Brophy Michael Burkes Officer - CHIEF FINANCIAL OFFICER SELL $93.97 1,866 $175,344 67,542 -2.7%
2024-05-02 04:05 2024-04-29 Moshkevich Solomon Officer - PRESIDENT, CLINICALDIAGNOSTICS SELL $93.14 1,196 $111,394 115,833 -1.0%
2024-05-02 04:05 2024-04-29 Fesko John Officer - PRESIDENT, CHIEF BUS. OFFICER SELL $93.14 929 $86,526 110,748 -0.8%
2024-05-02 04:05 2024-04-29 RABINOWITZ DANIEL Officer - SEC. AND CHIEF LEGAL OFFICER SELL $93.14 1,057 $98,448 204,495 -0.5%
2024-05-02 04:05 2024-04-29 Chapman Steven Leonard Director, Officer - CEO AND PRESIDENT SELL $93.14 4,084 $380,378 226,235 -1.8%
2024-05-02 04:05 2024-04-29 Brophy Michael Burkes Officer - CHIEF FINANCIAL OFFICER SELL $93.14 1,238 $115,306 69,408 -1.8%
2024-04-27 04:35 2024-04-25 Sheena Jonathan Director, Other SELL $89.55 1,000 $89,550 69,082 -1.4%
2024-04-27 04:35 2024-04-24 Brophy Michael Burkes Officer - CHIEF FINANCIAL OFFICER SELL $91.67 2,393 $219,365 70,646 -3.3%
2024-04-24 04:35 2024-04-23 RABINOWITZ DANIEL Officer - SEC. AND CHIEF LEGAL OFFICER OPT+S $91.38 787 $71,915 205,552 0.0%
2024-04-24 04:35 2024-04-23 Moshkevich Solomon Officer - PRESIDENT, CLINICALDIAGNOSTICS SELL $91.38 531 $48,522 117,029 -0.5%
2024-04-24 04:35 2024-04-23 Fesko John Officer - PRESIDENT, CHIEF BUS. OFFICER SELL $91.38 522 $47,700 111,677 -0.5%
2024-04-24 04:35 2024-04-23 Chapman Steven Leonard Director, Officer - CEO AND PRESIDENT OPT+S $91.38 2,552 $233,200 230,319 0.0%
2024-04-24 04:35 2024-04-23 Brophy Michael Burkes Officer - CHIEF FINANCIAL OFFICER OPT+S $91.38 1,523 $139,171 73,039 0.0%
2024-04-18 04:05 2024-04-16 Moshkevich Solomon Officer - PRESIDENT, CLINICALDIAGNOSTICS SELL $90.82 80,000 $7,265,648 117,560 -40.5%
2024-04-18 04:05 2024-04-15 Chapman Steven Leonard Director, Officer - CEO AND PRESIDENT SELL $93.13 6,816 $634,797 227,710 -2.9%
2024-04-05 04:35 2024-04-03 Sheena Jonathan Director, Other SELL $92.47 26,700 $2,468,821 321,031 -7.7%
2024-04-05 04:35 2024-04-02 Brophy Michael Burkes Officer - CHIEF FINANCIAL OFFICER SELL $92.62 1,378 $127,629 70,646 -1.9%
2024-03-30 04:35 2024-03-28 Sheena Jonathan Director, Other OPT+S $90.16 1,447 $130,456 69,582 0.0%
2024-03-30 04:35 2024-03-28 RABINOWITZ DANIEL Officer - SEC. AND CHIEF LEGAL OFFICER OPT+S $90.42 743 $67,179 204,839 0.0%
2024-03-30 04:35 2024-03-28 Moshkevich Solomon Officer - PRESIDENT, CLINICALDIAGNOSTICS SELL $90.42 707 $63,924 197,560 -0.4%
2024-03-30 04:35 2024-03-28 Fesko John Officer - PRESIDENT, CHIEF BUS. OFFICER SELL $90.42 464 $41,953 112,199 -0.4%
2024-03-30 04:35 2024-03-15 Chapman Steven Leonard Director, Officer - CEO AND PRESIDENT OPT+S $89.09 53,572 $4,772,751 234,526 0.0%
2024-03-30 04:35 2024-03-28 Brophy Michael Burkes Officer - CHIEF FINANCIAL OFFICER OPT+S $90.42 914 $82,640 72,024 0.0%
SHOW ENTRIES

How to Interpret $NTRA Trades

Not every insider transaction in Natera, Inc. is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $NTRA shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.

Data Source & Accuracy for NTRA

Insider activity data for Natera, Inc. is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $NTRA, allowing you to follow the capital of those with the most intimate knowledge of the company.

UNDERSTANDING THE DATA

FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.

TRADE DATE: The actual day the insider executed the purchase or sale in the market.

INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.

OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.

CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.

TRADE TYPES DEFINITIONS

BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.

SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.

OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.